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for presenting bilateral breast carcinomas (7), second tumors (19), loss of tracking or overprinting boost in another center (49).
22.11% were stage 0, 12.01% stage I, 22.58% stage II and 1.38% stage III. All women received 2D-radiotherapy to additional doses
of 45–50.4Gy and 10–14Gy as an additional boost on a surgical bed to standard fractionation. In the case of patients with more
than three positive axillary nodes they also received 45–50.4Gy on supraclavicular fossa.
Results. The median follow-up was 12.9 years (95% CI: 2.1–13.8 years). 10-Year local control and overall survival was 98.2% and
96.8%, respectively. By stages 10-year survival rates were 100% in stage 0, 99.1% in stage I and 87.5% in stage II. Stage III was not
assessable by the low sample size. Regarding local control rates at 10 years in stages 0, I and II, were about 100%, 97.5% and 97.9%,
respectively. The majority of the systemic recurrences were at bone level.
Conclusions. The data obtained in our hospital conﬁrm the excellent results of the combined treatments in the early stages of
breast cancer being comparable to those published in literature.
http://dx.doi.org/10.1016/j.rpor.2013.03.114
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Introduction. The S-BBC is a very rare disease, accounting for only 1–3% of all breast cancers. We have received in our center seven
cases of S-BBC. The treatment relies on surgery, chemotherapy and radiation therapy. No standard treatment guidelines exist
for the management of S-BBC. Current evidence indicates similar survival rates compared to early-staged breast cancer. The
difﬁculty in treatment planning varies greatly case by case therefore is a great challenge for radiotherapy planning.
Materials and methods. We report a review of one case. A 46 years old woman presented S-BBC in 2003. The patient presented
nodules in both breasts. The mammography revealed bilateral suspicious lumps and no suspicious lymph nodes. The extension
study showed no distant metastasis. The patient was scheduled for bilateral tumorectomy and axillary lymphadenectomy. The
histological diagnose was right breast invasive ductal carcinoma, pT1cpN1aM0, high grade and positive hormonal receptors, and
left breast colloid carcinoma, pT1cpN0M0, positive hormonal receptors. The patient received adjuvant chemo and radiotherapy.
The volume of treatment was delivered to the whole breast followed by a boost dose to the tumor bed, bilaterally. The supra-
clavicular and axillary lymph nodes of right breast were also treated. The energy used was 6MV on LINAC. The dose was 45Gy
(1.8Gy per fraction). The tumor bed received an additional dose of 10Gy with 10MeV electrons. Early side effects were bilateral
G1 epitelitis. In the follow-up the patient showed no local relapses or distant metastasis.
Conclusion. The challenges of the treatmenthavebeen raised concerninghow to reducedoseof radiation tonormal tissues, prevent
overdose due to overlap in midline tangential ﬁelds, while maintaining tumour control and minimizing secondary effects.
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Introduction. Traditionally, the administration of the boost in the conservative treatment of breast cancer has been performed
sequentially. The 3DRT-SIB technique (three-dimensional conformal simultaneously integrated boost) allows to reduce the total
time of treatment.
Purpose. Assessment of the acute toxicity in patients treated with 3DRT-SIB.
Methods and materials. Between May 2010 and May 2012, 150 women were treated in our Unit after being operated on for breast
carcinoma with conservative surgery. 33 patients received neoadjuvant chemotherapy (22%), 61 patients received adjuvant
chemotherapy (41%) prior to radiotherapy. Their ages were comprised between 28 and 84 years old (average 57 years old). Post-
surgical stage: pT0 (post-QT) 8%, pT1 66%, pT2 23%, pT3 2% and pT4 1%; pN0 69%, pN1 28%, pN2 2% and pN3 1%. None of them
showed distant metastases. The total dose administered to the mammary gland was 42.4Gy or 50Gy, delivering a simultaneous
boost with photon in the lumpectomy area. 0.4Gy per fraction in 82% and 0.6Gy per fraction in 18% were administered, reaching a
total dose ranged from 52.4 to 66Gy. Among the total of women, 24 of them (over 65 years old) were treated with hypofractionated
treatment, administering 2.65Gy daily with concomitant boost of 0.6Gy per fraction, reaching a dose of 54.4Gy in 16 fractions.
Results. We valued the dermal acute toxicity according to Common Terminology Criteria for Adverse Events (CTC v3.0), observing
radiodermatitis G0 9%, G1 55%, G2 31% and G3 4%. No acute toxicity was observed in G4. In patients with hypofractionated
treatment, toxicity was G0 8%, G1 74% and G2 21%, detecting no acute effect equal to or greater than G3.
Conclusions. The treatment with 3DRT-SIB is safe, presenting a similar toxicity to sequential boost with electrons, and allowing a
reduction of the total time of radiotherapy of 1–2 weeks.
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